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Background: This study performed at the National Research Institute of Tuberculosis and
Lung  Disease, Tehran, Iran, aimed to evaluate the effect of concomitant pulmonary hyper-
tension  on the outcome of pulmonary tuberculosis.
Methods: New cases of pulmonary tuberculosis were recruited for the study. Pulmonary
hypertension  was  deﬁned as systolic pulmonary arterial pressure ≥35 mm Hg estimated by
transthoracic Doppler echocardiography. We assessed the relationship between pulmonary
hypertension  and mortality during the six-month treatment of tuberculosis.
Results:  Of 777 new cases of pulmonary tuberculosis, 74 (9.5%) had systolic pulmonary arte-
rial  pressure ≥35 mm Hg. Ten of them (13.5%) died during treatment compared to 5% of cases
with  pulmonary arterial pressure less than 35 mm Hg (p = 0.007). Logistic regression analysis
showed  that pulmonary hypertension and drug abuse remained independently associated
with  mortality (OR = 3.1; 95% CI: 1.44–6.75 and OR = 4.4; 95% CI: 2.35–8.17, respectively).ant aConclusion: A signiﬁcmonary  hypertension and
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Introduction
Pulmonary tuberculosis (TB) continues to be a major
health problem worldwide. In spite of effective chemother-
apy,  excess morbidity and mortality are attributed to TB.
Because  treatment success in pulmonary TB has been
deﬁned as mycobacteriological response, little attention has
been  paid to the related chronic disabilities in those who
survived  the disease.1 Despite successful treatment, a sig-
niﬁcant  permanent damage of lung function has been
reported in more  than 50% of pulmonary TB patients.
They may  be obstructive or restrictive2 and lead to gas
exchange abnormalities and development of pulmonary
hypertension.3
Pulmonary hypertension (PH) is a serious disorder with
poor  prognosis. It is deﬁned as a mean pulmonary arterial
pressure (PAP) of more  than 25 mm Hg at rest.4 Recently, new
therapeutic  options have been developed for treating PH that
improve  quality of life and prognosis of the disease.5 Symp-
toms  of PH consisting of dyspnea, palpitations, fatigue, and
syncope  are vague that postpone detection of it.4 As a result,
an  appropriate plan for screening PH is necessary among high
risk  groups of patients.
Few  studies described PH in treated TB patients but most
of  them were  conducted during pre-chemotherapy era.6 Stud-
ies  about PH during active pulmonary TB are very scarce.7
Moreover, according to different deﬁnitions of the disease and
various  screening methods and population groups, the results
are  widely different.
This  study was  aimed to evaluate the effects of PH in the
outcome  of active pulmonary TB. Due to the growing range of
therapeutic  options, early diagnosis of pulmonary hyperten-
sion  may  change patient survival.
Materials  and  methods
This retrospective cohort study was  conducted on inpatient
new  cases of pulmonary tuberculosis that were  diagnosed
in  the National Research Institute of Tuberculosis and Lung
Diseases  (NRITLD), Tehran, Iran between 2005 and 2009. A
diagnosis  of TB was  made by positive smear and culture results
for  Mycobacterium tuberculosis or histopathological ﬁndings.
New  cases of TB were  deﬁned as those who had received
either no anti-TB drugs or less than one month of treatment
in  the past. TB treatment has been initiated at the time of
diagnosis,  as recommended by the World Health Organization
(WHO)  guidelines,8 consisting of isoniazid, rifampin, ethamb-
utol  and pyrazinamide for two months as initial phase and
isoniazid  and rifampin for the next four months as main-
tenance  phase. All the patients were  referred to peripheral
health centers for continuing medication under the directly
observed  treatment (DOT) strategy in accordance with our
National  Tuberculosis Program (NTP). The outcome of treat-
ment  was  deﬁned according to WHO  guidelines. Death due to
any reason during the course of tuberculosis treatment was
considered.8
For calculation of pulmonary artery pressure ﬁrstly tri-
cuspid  valve regurgitant jet was  identiﬁed by color Doppler 1 4;1  8(5):487–490
echocardiography (Vivid 7 dimension; Mann healthcare, GE).
Then  the trans-tricuspid pressure gradient was  calculated
using  modiﬁed Bernoulli equation and right atrium pres-
sure  was  added to obtained peak pulmonary artery pressure.
For  this study we considered pulmonary hypertension as
peak  systolic pulmonary arterial pressure equal or more  than
35  mm Hg estimated by resting transthoracic echocardiogra-
phy.
Recorded data of all new cases of pulmonary tuberculosis
from our hospital registry were preset for recent study. Demo-
graphic,  characteristics and other variables were  entered in
SPSS  (version 11.5) software.
The relationship between pulmonary hypertension and
the  outcome of TB treatment was  assessed controlling for
confounding factors (age, sex, smoking, drug abuse, symp-
toms  and adverse effects of anti TB drugs) by regression
analysis. The 2 test was  used for categorical variables, and
whenever  necessary, the Fisher exact test was  utilized. Con-
tinuous  variables with normal distribution were  analyzed by
t-Student test, and Mann–Whitney U test in case of abnor-
mal  distribution. A p-value < 0.05 was considered statistically
signiﬁcant.
The  scientiﬁc and ethics committee of the NRITLD
approved the study protocol.
Results
A total of 777 new cases of pulmonary tuberculosis were
diagnosed in the study period. Systolic pulmonary arterial
pressure more  than 35 mm Hg was  detected in 74 (9.5%) by
Doppler  echocardiography. Right heart catheterization was
not  performed.
Characteristics of patients and clinical factors for both
groups  are showed in Table 1.
Males comprised 357 (45.9%). Mean (±SD) age of patients
was  54.51 ± 21.73; 84% were of Iranian nationality. HIV test
was  performed in 309 patients with 36 (4.7% of all cases)
positive cases. All TB patients with PAP ≥ 35 mm were  HIV neg-
ative.
There  was  no signiﬁcant difference between patients with
PAP  above and below 35 mm Hg concerning gender, smoking
status,  opium addiction, and history of hemoptysis.
Cases with pulmonary hypertension were  older and
present dyspnea and chest pain more  often.
Adverse effects of anti-TB medications occurred in 26
(35%)  patients with PAP ≥ 35 mm Hg and in 38% patients of
the  control (p = 0.68). The major adverse effect was  drug-
induced hepatitis, which was  not different between two
groups  (p = 0.18).
The outcome of TB treatment was known for 700 patients.
Ten  patients with PAP ≥ 35 mm Hg (13.5%) died during treat-
ment  in comparison to 5% of cases without PH (p = 0.007)
(Fig.  1).
To  determine the independent association of risk fac-
tors  (gender, age > 65, nationality, smoking status, and
PAP  ≥ 35 mm Hg) with mortality, a logistic regression was  per-
formed.  Drug abuse and PAP ≥ 35 mm Hg were  the factors that
remained  independently associated with mortality in the ﬁnal
model  (Table 2).
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Table 1 – Characteristics of TB patients with and without pulmonary hypertension.
Variables PAP ≥ 35 mm Hg
n (%)
PAP  < 35 mm Hg
n  (%)
p-value
Gender
Male 34 (45.9) 323 (45.9) NS
Female  40 (54.1) 380 (54.1)
Age (mean ± SD) 68.50 ± 15.56 52.99 ± 21.78 <0.001
Smoker 23 (31.1) 183 (26) NS
Opium addiction 14 (18.9) 131 (18.6) NS
Hemoptysis 8 (10.8) 127 (18.1) NS
Chest pain 42 (56.8) 311 (44.3) 0.049
Dyspnea 66 (89.2) 470  (66.9) <0.001
Total 74  703
PAP, pulmonary artery pressure; NS, not signiﬁcant.
Table 2 – Relationship between independent risk factors and death in TB patients.
Variables p-value OR (95% CI)
Gender 0.41 – –
Nationality 0.76 – –
Smoking 0.14 – –
Age > 65 0.64 – –
PAP ≥ 35 mm Hg 0.004 3.12 (1.44–6.75)
Drug abuse 0.001  4.38 (2.35–8.17)
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verall, we  found a 9.7% prevalence of pulmonary artery pres-
ure  equal or more  than 35 mm Hg among patients with active
ulmonary  tuberculosis. Patients with higher PAP were older
nd  present with dyspnea more  often. Mortality rate was
igher  among cases with PAP equal or more  than 35 mm Hg.
Since the 19th century myocardial damage has been found
n  autopsy studies in pulmonary tuberculosis patients.9
ccentuated 2nd heart sound over the pulmonary area
f  chronic TB patients is associated with an unfavorable
10utcome.
Association of active tuberculosis and pulmonary hyper-
ension  has been assessed in few previous studies, in which
700
600
500
400
300
200
100
0
PAP≥35 mmHg PAP <35 mmHg
Alive
Death
ig. 1 – Distribution of deaths in two groups of TB patients.
ata  was  available for 700 patients. PAP, pulmonary artery
ressure.PH  or cor pulmonale was  diagnosed either by electrocardiogra-
phy or post-mortem.6 Cor pulmonale was  the cause of death
at  necropsy in 23% of TB patients in one study with over 50% of
these  patients with a history of clinical signs related to cardiac
failure  before death.10
In a cross sectional study Ahmed and colleagues described
14  patients who presented with shortness of breath after
successful treatment of pulmonary tuberculosis. PH was  con-
sidered  as pulmonary artery systolic pressure ≥ 40 mm Hg
estimated  by Doppler echocardiography. Most of them had
ﬁbro  cavitary or ﬁbrotic changes in the chest X-ray. Their work
is  different from ours as none of their cases had active TB and
the  mean interval since TB diagnosis was  9.4 years.6
In a study with 52 new cases of pulmonary tuberculosis
44.2% had systolic pulmonary artery pressure above 25 mm Hg
by echocardiography. All the patients were young and majority
of  them had disseminated disease or involvement of intra-
thoracic  lymphatics.7
In our study, death was  signiﬁcantly higher among patients
who  had PAP ≥ 35 mm Hg. This ﬁnding is not in line with the
results  obtained by Tomono showing no association between
PH  and late sequela of TB. Comparison of these results to the
present  study may  be problematic as we investigated active
TB  cases and short-term outcome as opposed to old TB cases
and  long-term outcomes of the Japanese study.11
Pathogenesis of pulmonary arterial hypertension among
TB  patients is not clear. In the past some suggested that
repeated secondary infections in residual cavities and scar
lesions  of healed TB might have a role. Exudative secreti-
ons  cause respiratory passage blockage, impairment in gas
exchange  and ultimately rising cardiac output.9 Nonetheless,
this  theory does not justify the reason for high pulmonary
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arterial pressure of active and new cases of TB. Active tuber-
culosis  by unknown mechanisms may  be directly responsible
for  rising PAP. Moreover, PH may  be related to parenchymal
destruction and hypoxia in the course of the disease espe-
cially  in case of delayed diagnosis and initiation of anti-TB
treatment. Concomitant lung diseases such as COPD as well
as  myocardial involvement could be the cause of PH.
The  overall ﬁndings of our study corroborate the results
of  previous studies concerning the relevance of PH in TB
patients,  but our study was  conducted in active TB cases and
evaluated  short-term outcomes. Although the current study
has  some strong points such as large number of cases, there
are  some important limitations. First, echocardiography had
not  been performed in all cases, which may  have underes-
timated diagnosis of PH. Second, other causes of PH such
as  concomitant pulmonary disease have not been ruled out.
Finally,  diagnosis of PH had not been conﬁrmed by right heart
catheterization (RHC). Although RHC is the gold-standard
procedure and necessary for PH conﬁrmation,12 it is an inva-
sive  and expensive procedure, unsuitable as a screening tool.
Transthoracic  Doppler echocardiography has been shown to
be a safe, sensitive and speciﬁc method for screening PH in
patients  with systemic diseases like systemic sclerosis and
lupus  erythematosus.13,14 Measurement of PAP by echocar-
diography in patients with severe tricuspid regurgitation may
lead  to underestimation. Also overestimation is common.15
So echocardiography may  be not a suitable screening tool for
asymptomatic patients with mild PH.12 Several cut-off points
of  PAP were  used by investigators when screening for PH
with  Doppler echocardiography, such as 30 mm Hg,13 40 mm
Hg,6 and 50 mm Hg.14 The European Society of Cardiology
and the European Respiratory Society suggest arbitrary crite-
ria  for diagnosing PH based on Doppler calculation and other
echocardiographic ﬁndings.12
Although our study shows the relevance of PH in active pul-
monary  tuberculosis, there remains many  unresolved issues:
what  are the risk factors of PH among TB patients? Is screening
of  PH indicated for the cases of pulmonary TB, minimally for
those  who are high risk for PH? What is the optimal tool for
such  screening? After detection of PH, is there any interven-
tion  that could improve outcome of TB patients? Prospective
well-designed studies are necessary to respond these ques-
tions.
Conclusion
Pulmonary hypertension is common among active pulmonary
tuberculosis patients and needs more  attention. Higher
pulmonary artery pressure in Doppler echocardiography is
signiﬁcantly associated to mortality among new cases of pul-
monary  tuberculosis. 1 4;1  8(5):487–490
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